Supercritical CO2-Processed Micronized Acellular Dermal Matrix Enhances Soft-Tissue Regeneration: A Preclinical and Clinical Study
BACKGROUND: Micronized acellular dermal matrix (mADM) derived from decellularized human dermis is used in breast reconstruction to address soft-tissue deficiencies and peri-implant deformities. Although mADM processed using supercritical carbon dioxide (SC-mADM) has previously been evaluated with respect to its fabrication and biocompatibility, its clinical application has not yet been investigated. Therefore, we aimed to evaluate the biological responses to SC-mADM and its preliminary clinical applicability as an injectable scaffold. METHODS: In a rabbit model, 3 mL of either low-concentration (7.5%) or high-concentration (25%) SC-mADM was injected and assessed at 3 and 6 months. Volume retention was quantified using micro-computed tomography. Histologic analyses and quantitative reverse transcription polymerase chain reaction analyses of genes associated with angiogenesis and tissue remodeling were performed. Based on these findings, a prospective clinical study involving four patients and five breasts was conducted to assess the correction of post-reconstruction rippling. RESULTS: High-concentration SC-mADM demonstrated greater volume retention than low-concentration SC-mADM at both 3 and 6 months. At 6 months, CD31-positive vascular density was higher in the high-concentration group, accompanied by increased expression of angiogenesis- and remodeling-related genes. Clinically, injections of high-concentration mADM resulted in improvement in rippling and peri-implant depressions. Magnetic resonance imaging at 4 months demonstrated an early mean region-level volume retention rate of 57.6%. CONCLUSIONS: Injected mADM exhibited concentration-dependent tissue integration. These preliminary findings suggest that SC-mADM may serve as a biologically active injectable scaffold for minimally invasive contour correction in breast reconstruction. Further validation in larger studies with longer follow-up periods is warranted.Clinical Relevance Statement: mADM is a promising advanced soft-tissue filler that supports volume retention and host-tissue integration. The biological responses observed in the rabbit model provide preclinical evidence supporting its potential use in soft-tissue augmentation and repair.
Authors
- Sehoon Yoon
- Duri Lee
- Yongwoo Shin (ORCID: https://orcid.org/0000-0002-1256-6429)
- Ki Yong Hong (ORCID: https://orcid.org/0000-0002-8579-0237)
- Chang Hak
- Heewoong Yang (ORCID: https://orcid.org/0009-0002-6844-6183)
- Eun Hee Yeon
- Ying Zhu
- Jin Woo Bae
- Haejin Lew
Institutions
- Seoul National University (KR)
- Seoul National University Hospital (KR)
Publication Details
- Journal
- Plastic & Reconstructive Surgery
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1097/prs.0000000000013608
- Primary Topic
- Tissue Engineering and Regenerative Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00